TPSAB1 Mouse Monoclonal Antibody
- Known as:
- TPSAB1 Mouse Monoclonal Antibody
- Catalog number:
- ENZ-007177-M01
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- TPSAB1 Mouse Monoclonal Antibody
Related genes to: TPSAB1 Mouse Monoclonal Antibody
- Gene:
- TPSAB1 NIH gene
- Name:
- tryptase alpha/beta 1
- Previous symbol:
- TPSB1, TPS1, TPS2
- Synonyms:
- -
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-11-07
- Date modifiied:
- 2015-09-08
Related products to: TPSAB1 Mouse Monoclonal Antibody
Related articles to: TPSAB1 Mouse Monoclonal Antibody
- Clear cell renal cell carcinoma (ccRCC) exhibits substantial molecular and immune heterogeneity. Mast cells participate in tumor-microenvironment remodeling, but the prognostic relevance of mast cell-associated apoptosis-related transcriptional features remains unclear. - Source: PubMed
Publication date: 2026/09/03
Guan RijianWan LijunFeng Chunyun - Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly immunosuppressive tumour microenvironment (TME), which contributes to its resistance to immunotherapy. Although mast cells (MCs) have been implicated in PDAC progression, their functional heterogeneity and candidate signaling models of immune modulation remain poorly understood. - Source: PubMed
Publication date: 2026/08/31
Wu MengliYe XuXiaYu QiHuang HuiZhang ZhezhongYu XiaoliLou SongmeiXu Jian - Allergic diseases have been linked to genetic variations in TPSAB1 and TPSB2. This study aimed to develop a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) method for simultaneous copy number detection of TPSAB1 and TPSB2. - Source: PubMed
Li YangZhao XuefengHe ShengLai YunliWei ShijieZhou Wanjun - COVID-19 does not require hospitalization in most cases, but post-acute sequelae can persist and are a public health concern. In a prospective cross-sectional study, we examine persistent ocular symptoms (POS) emerging in non-hospitalized individuals after COVID-19, with individuals without POS post-recovery as controls. Using symptom and quality of life data, clinical examinations and biofluid proteomics, we document ocular symptoms persisting from 3 months up to 3 years post-infection. POS lead to significant vision disability and are linked to clinical findings not detectable in routine exams but only with specialized tests. POS include near vision disturbances, strabismus, weakened autonomic pupillary reflexes, corneal neurodegeneration and chronic activation of ocular surface dendritic/T cells. We report a tear film proteomic profile consistent with severe COVID-19, chronic dysregulation of CD4 T cell regulatory activity, upregulation of ITGB6, NFASC, CTGF, TPSAB1 and CKMT1A-CKMT1B, pupil dysfunction correlating with elevated JUN, and dendritic/T cell dysregulation correlating with elevated ANGPTL2, SKAP2 and DAPP1 levels. Diagnostic models based on clinical examinations with or without biomarkers predict POS with 77-91% accuracy and implicate chronic T cell-mediated neuroinflammation in the pathogenesis of POS, a debilitating syndrome arising after COVID-19 recovery and characterized by strabismus, ocular dysautonomia and peripheral ocular neuropathy. - Source: PubMed
Publication date: 2026/07/08
Moustardas PetrosSetterud HelenMeijer HelenaAndersson GunnelRoth JennyDashti AvaJohansson BjörnMacedo António FilipeLagali Neil - Hereditary α-tryptasemia (HαT) is a common autosomal-dominant trait caused by additional copies of the gene encoding for α-tryptase. This inheritance is the most common etiology for elevated basal serum tryptase (BST), occurring almost exclusively at BST ≥ 8 μg/L. In systemic mastocytosis (SM) and nonclonal mast cell-mediated disorders, HαT is linked to a complex constellation of symptoms. - Source: PubMed
Publication date: 2026/05/20
Koch DanielWortmann FriederikeRecke AndreasRose EllenGaffal EvelynWigger Jennifervon Bubnoff Nikolasvon Bubnoff Dagmar